Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 25, 2013 - Issue 8
247
Views
22
CrossRef citations to date
0
Altmetric
Research Article

Subchronic toxicity and carcinogenicity studies of 1,2-dichloropropane inhalation to mice

, , , &
Pages 435-443 | Received 03 Mar 2013, Accepted 23 Apr 2013, Published online: 01 Jul 2013
 

Abstract

The subchronic toxicity and carcinogenicity of 1,2-dichloropropane (DCP) in male and female B6D2F1 mice exposed to DCP by inhalation for 13 weeks or for 2 years was investigated. The DCP concentrations used were 50, 100, 200, 300 or 400 ppm (v/v) in the 13-week study, and 32, 80 or 200 ppm (v/v) in the 2-year study. Thirteen weeks inhalation exposure of mice to DCP caused death in the mice exposed to 300 ppm and above, and was found to induce hemolytic anemia and lesions of the liver, forestomach and heart. Two years exposure to DCP significantly increased the combined incidence of bronchiolo-alveolar adenomas and carcinomas in females and marginally increased the incidence of Harderian gland adenomas in males. As non-neoplastic lesion, atrophy and respiratory metaplasia in the olfactory epithelium, and respiratory metaplasia in the submucosal gland of the nasal cavity were increased. Thus, two years inhalation exposure to DCP is carcinogenic in female mice and there is a marginal evidence of carcinogenicity in males.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.